(Q51819771)

13 April 2018

title

Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization. (English)

1 reference

13 April 2018

1 reference

G Wu

1

1 reference

13 April 2018

N Chai

2

1 reference

13 April 2018

Irene Kim

3

1 reference

13 April 2018

A S Klein

4

1 reference

13 April 2018

S C Jordan

5

1 reference

13 April 2018

publication date

1 March 2013

1 reference

13 April 2018

published in

Transplant Immunology

1 reference

13 April 2018

volume

28

1 reference

13 April 2018

issue

2-3

1 reference

13 April 2018

page(s)

138-143

1 reference

13 April 2018

Therapeutic targeting of the interleukin-6 receptor.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Clinical value of blocking IL-6 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Markers of inflammation before and after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

IL-6 promotes cardiac graft rejection mediated by CD4+ cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

The impact of Th17 cells on transplant rejection and the induction of tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Blockade of IL-6-signaling inhibits the pathogenesis of CD4+ T cell-mediated lethal graft-versus-host reaction against minor histocompatibility antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Interleukin-6 deficiency fails to prevent chronic rejection after aortic allografts in apolipoprotein E-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Prolonged renal allograft survival by donor interleukin-6 deficiency: association with decreased alloantibodies and increased intragraft T regulatory cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Induction of high-dose tolerance to the rat anti-mouse IL-6 receptor antibody in NZB/NZW F1 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Anti-CD3ε induces splenic B220lo B-cell expansion following anti-CD20 treatment in a mouse model of allosensitization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Follicular helper T cells as cognate regulators of B cell immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

The paradigm of IL-6: from basic science to medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Regulation of interleukin 6 receptor expression in human monocytes and monocyte-derived macrophages. Comparison with the expression in human hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

The impact of infection and tissue damage in solid-organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

The innate immune system in transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukaemia/HTLV-I-associated myelopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Activation of protein kinase C induces de novo synthesis of the soluble interleukin-6 receptor in human B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2013.03.003

10.1016/J.TRIM.2013.03.003

7 January 2021

Identifiers

DOI

1 reference

13 April 2018

1 reference

13 April 2018